We have continued our positive revenue and earnings momentum with our third consecutive quarter of sequential growth in both revenue and earnings per share. In Q2, we had record operating margins and record orders of the both the MiSeq instrument and MiSeq sequencing consumables. Second quarter 2012 revenue increased 3% sequentially to $281 million due to another successful quarter of MiSeq shipments, higher service revenue and continued growth in sequencing consumables.Revenue for the quarter decreased 2% compared to Q2 2011 as last year's quarter included a greater number of HiSeq sales. Instrument revenue for the second quarter was $72 million compared to Q2 2011. Instrument revenue was down 32%, again primarily due to decrease in sequencing and microarray instrumentation.
Illumina Management Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.